UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported) December 3, 2002
Advanced Biotherapy, Inc.
| Delaware | 0-26323 | 95-0402415 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6355 Topanga Canyon Boulevard, Suite 510 Woodland Hills, California (Address of principal executive offices) |
91367 (Zip Code) |
Registrant’s telephone number, including area code (818) 883-6716
| Item 5. OTHER EVENTS. | ||||||||
| Item 7. FINANCIAL STATEMENTS AND EXHIBITS | ||||||||
| Signatures | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Exhibit 99.1 | ||||||||
Item 5. OTHER EVENTS.
The registrant published a press release on December 2, 2002, which reported that Advanced Biotherapy, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for a utility patent for the use of any form of antibody to gamma interferon to treat corneal transplant rejection.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
| (c) | Exhibits. |
| Designation | Description of Exhibit | |
| 99.1 | Press Release, dated December 2, 2002 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADVANCED BIOTHERAPY, INC. (Registrant) |
||
| | ||
| Date: December 2, 2002 | By: | /s/Edmond Buccellato |
| Edmond Buccellato, President and CEO | ||
INDEX TO EXHIBITS
| Exhibit | Description | |
| 99.1 | Text of Press Release, dated December 2, 2002 |